Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects

The purpose of this study is to compare the pharmacokinetics of capsule and tablet formulations of TA-8995 in healthy male subjects aged 18 to 55 years.

Inclusion Criteria:

• Healthy males aged 18-55
• Body Mass Index (BMI) between 18.0 and 32.0 kg/m2, inclusive

Exclusion Criteria:

• Subject has a known hypersensitivity to any of the inactive ingredients of the study treatments.
• Subject has any other condition which, in the Investigator's opinion will interfere with the study.
• Subjects who are still participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) within 3 months or 5 half-lives (whichever is longer) prior to the first dose in this study.